Photo from Icahn School of Medicine at Mount Sinai/X
Aug 12, 2024, 13:49
SENTRY study – investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis
Icahn School of Medicine at Mount Sinai shared on X:
“The SENTRY study, led by Dr. John Mascarenhas, is investigating the safety and efficacy of the combination of selinexor (Xpovio) plus ruxolitinib (Jakafi) for the treatment of patients with JAK inhibitor treatment-naive myelofibrosis.”
Read further.
Source: Icahn School of Medicine at Mount Sinai/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12